MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2165/11597580-000000000-00000

Медицинская библиотека · American journal of cardiovascular drugs : drugs, devices, and other interventions · 2012

Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.

El-Menyar Ayman, AlHabib Khalid F, Al-Motarreb Ahmed, Hersi Ahmad, Al Faleh Hussam, Asaad Nidal, Al Saif Shukri, Almahmeed Wael, Sulaiman Kadhim, Amin Haitham, Al-Lawati Jawad, Alsheikh-Ali Alawi A, AlQahtani Awad, Al-Sagheer Norah Q, Singh Rajvir, Al Suwaidi Jassim

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Although antiplatelet therapy effectively reduces ischemic events, the cardiovascular (CV) outcome in some cases is still unpredictable.

OBJECTIVE

The objective of this study was to evaluate the impact of prior single or dual antiplatelet (PAP) use in patients presenting with acute coronary syndromes (ACS).

METHODS

Data were collected from the 2nd Gulf Registry of Acute Coronary Events between October 2008 and June 2009. Patients were grouped according to whether they were PAP users or not (NAP). Patients' characteristics and outcomes were analyzed and compared. Mortality was assessed at 1 and 12 months.

RESULTS

Among 7827 consecutive ACS patients, 41% were PAP users (70% aspirin, 1% clopidogrel, and 29% dual antiplatelet agents). In comparison with NAP use, PAP use was associated with a higher rate of co-morbidities, atypical presentation, severe left ventricular dysfunction, three-vessel disease, and a high GRACE risk score. After adjustment for relevant covariates, PAP use was an independent predictor for recurrent ischemia in unstable angina (odds ratio [OR] 1.7; 95% CI 1.17, 2.57) and non-ST-elevation myocardial infarction (NSTEMI) [OR 1.9; 95% CI 1.38, 2.65] and for heart failure in NSTEMI (OR 1.5; 95% CI 1.11, 2.15) and STEMI (OR 1.4; 95% CI 1.08, 1.93). Although PAP use was associated with high mortality in STEMI and NSTEMI, it was not an independent predictor for mortality. Among PAP patients, percutaneous coronary intervention independently reduced the risk of hospital (adjusted OR 0.25; 95% CI 0.20, 0.32), 1-month (OR 0.31; 95% CI 0.26, 0.37), and 12-month mortality (OR 0.28; 95% CI 0.24, 0.33).

CONCLUSION

PAP use identified a high-risk population across the ACS spectrum. Early coronary revascularization may improve CV outcomes in these patients.

Для цитирования: El-Menyar Ayman, AlHabib Khalid F, Al-Motarreb Ahmed, Hersi Ahmad, Al Faleh Hussam, Asaad Nidal, Al Saif Shukri, Almahmeed Wael, Sulaiman Kadhim, Amin Haitham, Al-Lawati Jawad, Alsheikh-Ali Alawi A, AlQahtani Awad, Al-Sagheer Norah Q, Singh Rajvir, Al Suwaidi Jassim. Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2012. DOI: 10.2165/11597580-000000000-00000.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.